Patents Assigned to CarsGEN Therapeutics Limited
  • Chimeric antigen receptors targeting GPC3 and uses thereof
    Patent number: 10731127
    Abstract: A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: August 4, 2020
    Assignee: CARsgen Therapeutics Limited
    Inventors: Zonghai Li, Huiping Gao, Hua Jiang, Bizhi Shi, Huamao Wang, Kesang Li, Hongyang Wang, Shengli Yang, Jianren Gu
  • Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
    Patent number: 10604740
    Abstract: A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302nd amino acid epitopes of a human epidermal growth factor receptor (EGFR).
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: March 31, 2020
    Assignee: CarsGEN Therapeutics Limited
    Inventors: Zonghai Li, Huiping Gao, Hua Jiang, Bizhi Shi